Three GLP-1-based compounds now dominate metabolic peptide research: semaglutide, tirzepatide, and retatrutide. Each generation adds receptor targets and — so far — meaningfully more weight reduction in published clinical trials. This article breaks down the mechanism, key trial data, and research profile of each, with direct links to the primary studies.
All compounds discussed are being evaluated in clinical research settings. FenaLife supplies these peptides for research purposes only.
Quick Comparison: What Each Compound Targets
| Compound | Receptor Targets | Developer | Approval Status (2026) |
|---|---|---|---|
| Semaglutide | GLP-1R | Novo Nordisk | FDA approved (Wegovy, Ozempic) |
| Tirzepatide | GLP-1R + GIPR | Eli Lilly | FDA approved (Zepbound, Mounjaro) |
| Retatrutide | GLP-1R + GIPR + GCGR | Eli Lilly | Phase 3 / Pre-approval |
Each step adds a receptor: tirzepatide adds GIP to semaglutide’s GLP-1 agonism; retatrutide adds glucagon on top of both. The clinical significance of each addition is visible in the trial weight-loss numbers.
Semaglutide: The Established Benchmark
Mechanism
Semaglutide is a GLP-1 receptor agonist — a synthetic analog of human glucagon-like peptide-1 with a fatty acid chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It acts on GLP-1 receptors in the pancreas (increasing insulin secretion in a glucose-dependent manner), the hypothalamus (reducing appetite), and the gut (slowing gastric emptying). Semaglutide is the first GLP-1 agonist to demonstrate significant weight loss in non-diabetic populations at the 2.4 mg dose.
Key Published Studies
STEP-1 Trial (Obesity, No Diabetes) — NEJM, 2021
- 1,961 participants with BMI ≥30 (or ≥27 with weight-related comorbidity), no type 2 diabetes
- 68 weeks, 2.4 mg subcutaneous semaglutide once weekly vs. placebo
- Mean weight loss: 14.9% vs. 2.4% placebo (placebo-adjusted: −12.4 percentage points)
- 86% of participants achieved ≥5% weight loss; 69% achieved ≥10%
- Most common adverse events: nausea (44%), diarrhea (30%), vomiting (24%) — predominantly mild-to-moderate and transient
SELECT Cardiovascular Outcomes Trial — NEJM, 2023
- 17,604 adults with preexisting cardiovascular disease, overweight/obesity, no diabetes
- Median follow-up: 39.8 months
- 20% reduction in major adverse cardiovascular events (MACE) — HR 0.80 (95% CI 0.72–0.90)
- Landmark finding: cardiovascular benefit independent of weight loss magnitude
- Established semaglutide as the first obesity medication with a proven CV outcomes benefit
Semaglutide Research Profile Summary
- Weight loss (obesity, no T2D): ~15% at 68 weeks
- Cardiovascular outcomes: Proven benefit (SELECT)
- Dosing: 0.25 mg escalating to 2.4 mg (obesity) or 1.0 mg (diabetes) subcutaneous weekly
- Half-life: ~7 days
- Mechanism advantage: Most extensively studied compound; largest long-term safety dataset
Tirzepatide: Dual Agonist, Bigger Numbers
Mechanism
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single peptide molecule that activates both receptors simultaneously. Adding GIP receptor agonism has two relevant effects: it potentiates insulin secretion beyond GLP-1 alone, and it appears to reduce the nausea burden compared to pure GLP-1 agonism. GIP receptors in adipose tissue may also contribute to lipid metabolism effects. The net result in trials has been meaningfully more weight loss than semaglutide head-to-head, with a comparable or slightly better tolerability profile.
Key Published Studies
SURMOUNT-1 Trial (Obesity, No Diabetes) — NEJM, 2022
- 2,539 participants with BMI ≥30 (or ≥27 with comorbidity), no type 2 diabetes
- 72 weeks, three doses: 5 mg, 10 mg, 15 mg once weekly
- Mean weight loss: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) vs. 3.1% placebo
- 37% of participants on 15 mg achieved ≥25% weight loss
- 91% achieved ≥5% weight loss on 15 mg dose
- Established tirzepatide as the most effective approved weight-loss medication at time of publication
SURPASS-2 Trial (Tirzepatide vs. Semaglutide, T2D) — NEJM, 2021
- 1,879 adults with type 2 diabetes inadequately controlled on metformin
- 40 weeks; tirzepatide 5/10/15 mg vs. semaglutide 1 mg once weekly
- A1C reduction: −2.01% (5 mg), −2.24% (10 mg), −2.30% (15 mg) vs. −1.86% (semaglutide 1 mg)
- Weight loss: −7.6 kg, −9.3 kg, −11.2 kg (tirzepatide) vs. −5.7 kg (semaglutide)
- First head-to-head trial demonstrating tirzepatide’s superiority over semaglutide across all doses for glycemic control and body weight in T2D
Tirzepatide Research Profile Summary
- Weight loss (obesity, no T2D): ~15–21% at 72 weeks depending on dose
- vs. Semaglutide head-to-head: Superior on weight loss and A1C at all doses (T2D population)
- Dosing: 2.5 mg escalating to 5/10/15 mg subcutaneous weekly
- Half-life: ~5 days
- Mechanism advantage: Dual agonism appears to provide additive/synergistic effect vs. GLP-1 alone; generally well-tolerated
Retatrutide: Triple Agonist, Phase 3 Results Now Published
Mechanism
Retatrutide (LY3437943) activates three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). The glucagon receptor addition is the critical differentiator. Glucagon receptor agonism increases energy expenditure — it stimulates hepatic glucose output, promotes lipolysis, and raises resting metabolic rate. In isolation, glucagon agonism would increase blood glucose; co-administered with GLP-1 and GIP agonism, the glucose effects are blunted while the energy expenditure benefits remain. This is the theoretical basis for retatrutide’s substantially larger weight-loss numbers vs. tirzepatide.
Key Published Studies
Phase 2 Trial (Obesity) — NEJM, 2023
- 338 adults with obesity (BMI ≥30), no type 2 diabetes
- 48 weeks; doses: 1 mg, 4 mg, 8 mg, 12 mg once weekly vs. placebo
- Mean weight loss at 48 weeks: 17.5% (4 mg), 22.8% (8 mg), 24.2% (12 mg)
- Placebo-adjusted weight loss at 12 mg: −22.8 percentage points at 48 weeks
- At 24 weeks, 12 mg group showed −16% weight vs. placebo — faster trajectory than tirzepatide Phase 2 data at comparable timepoints
- Adverse events: nausea, vomiting, diarrhea — similar GI profile to other GLP-1 agonists; no unexpected safety signals
TRANSCEND-T2D-1 Phase 3 Trial (Type 2 Diabetes) — The Lancet, 2026
- Phase 3, double-blind, randomized, placebo-controlled; adults with T2D inadequately controlled on diet/exercise (HbA1c 7.0–9.5%, BMI ≥23)
- 40 weeks; retatrutide 4 mg, 9 mg, 12 mg vs. placebo once weekly
- Mean A1C reduction: up to −2.0% — meeting all primary and secondary endpoints
- Mean body weight loss: up to −16.8% (36.6 lb) at 40 weeks
- Results presented at ADA 86th Scientific Sessions and simultaneously published in The Lancet, June 2026
- Seven additional Phase 3 readouts pending: liver disease (NASH), sleep apnea, cardiovascular outcomes, and others expected 2026–2027
Retatrutide Research Profile Summary
- Weight loss (obesity, Phase 2): ~24% at 48 weeks (12 mg)
- Weight loss (T2D, Phase 3): ~16.8% at 40 weeks
- vs. Tirzepatide: No direct head-to-head trial yet; cross-trial comparison suggests meaningfully larger weight reduction
- Dosing: 2 mg escalating to 4/8/12 mg subcutaneous weekly
- Approval status: Phase 3 ongoing; not yet approved in any country as of June 2026
- Mechanism advantage: Glucagon receptor agonism drives energy expenditure — a genuinely different lever vs. appetite suppression alone
Head-to-Head Weight Loss Comparison (Published Trial Data)
| Compound | Population | Duration | Peak Mean Weight Loss | Source |
|---|---|---|---|---|
| Semaglutide 2.4 mg | Obesity, no T2D | 68 weeks | 14.9% | STEP-1, NEJM 2021 |
| Tirzepatide 15 mg | Obesity, no T2D | 72 weeks | 20.9% | SURMOUNT-1, NEJM 2022 |
| Retatrutide 12 mg | Obesity, no T2D | 48 weeks | 24.2% | Phase 2, NEJM 2023 |
| Retatrutide 12 mg | T2D | 40 weeks | 16.8% | TRANSCEND-T2D-1, Lancet 2026 |
Important caveat: These trials used different populations, durations, and designs — direct numerical comparison across trials is not equivalent to a randomized head-to-head study. No head-to-head trial of retatrutide vs. tirzepatide or semaglutide has been published as of June 2026.
The Glucagon Receptor: Why Retatrutide’s Third Target Matters
The incremental weight-loss numbers between semaglutide and tirzepatide (~5 percentage points) roughly track with adding a second receptor. Retatrutide’s numbers suggest the glucagon receptor adds another ~4–5 percentage points on top.
The mechanism is distinct from the appetite pathway. GLP-1 and GIP agonism primarily reduce caloric intake through satiety signaling. Glucagon receptor agonism increases energy expenditure — it raises hepatic glucose production (counteracted by the GLP-1/GIP component), promotes fatty acid oxidation, and elevates thermogenesis. In the context of a triple agonist, you’re theoretically hitting both sides of the energy balance equation: reduced intake and increased expenditure.
Researchers have noted the glucagon component may also have beneficial effects on hepatic lipid metabolism, which is why several retatrutide trials are targeting non-alcoholic steatohepatitis (NASH/MASH) as an endpoint — a disease area where neither semaglutide nor tirzepatide has an approved indication yet.
Adverse Event Profiles: What the Trials Report
All three compounds share the same primary adverse event profile — GI effects driven by GLP-1 agonism: nausea, vomiting, diarrhea, constipation. These are dose-dependent and most prominent during dose escalation.
| AE Category | Semaglutide (STEP-1) | Tirzepatide (SURMOUNT-1) | Retatrutide (Phase 2) |
|---|---|---|---|
| Any GI AE | ~62% | ~65% | ~73% |
| Nausea | 44% | 31% | ~45% |
| Vomiting | 24% | 16% | ~25% |
| Diarrhea | 30% | 23% | ~27% |
| Discontinuation due to AEs | 7% | 6.7% | 8–16% (dose-dependent) |
Tirzepatide’s lower nausea rate compared to semaglutide is frequently noted as a potential tolerability advantage, attributed to the GIP component modulating GI motility effects. Retatrutide’s higher discontinuation rate at maximum dose warrants monitoring in Phase 3 safety data.
Additional Published References
- Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Phase 2a, Nature Medicine 2024
- STEP-1: Semaglutide in Obesity (No Diabetes) — NEJM 2021
- SURMOUNT-1: Tirzepatide in Obesity (No Diabetes) — NEJM 2022
- SURPASS-2: Tirzepatide vs. Semaglutide in T2D — NEJM 2021
- Retatrutide Phase 2 (Obesity) — NEJM 2023
- TRANSCEND-T2D-1: Retatrutide Phase 3 (T2D) — The Lancet 2026
- SELECT: Semaglutide Cardiovascular Outcomes — NEJM 2023
All compounds discussed are available from FenaLife for research use only. Each order ships with a Certificate of Analysis from an independent third-party lab. View our full compound catalog or use the reconstitution calculator for BAC water preparation guidance.
🔬 Research Compounds Referenced: Retatrutide 10mg | Tirzepatide 10mg | Semaglutide 10mg